Happel David's Insider Trades & SAST Disclosures

Happel David's most recent trade in Sagimet Biosciences Inc - Ordinary Shares - Class A was a trade of 65,478 Series A Common Stock done at an average price of $9.1 . Disclosure was reported to the exchange on July 21, 2025.

Share

Note

This is a custom search result for pattern Happel David.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.

All Superstars

"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches "Balanced Fund" but not "Balanced Growth Fund" Balanced Fund: Use this format without quotation marks to search for all funds related to the term "Balanced Fund" The results may include "Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".

Stock	Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Sagimet Biosciences Inc - ...	David Happel	Director, President & CEO	Sale of securities on an exchange or to another person at price $ 9.13 per share.	21 Jul 2025	65,478	689,722	-	9.1	598,115	Series A Common Stock
Sagimet Biosciences Inc - ...	David Happel	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Feb 2025	472,000	472,000	-		-	Stock Option (Right to Buy)
Sagimet Biosciences Inc - ...	David Happel	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Feb 2025	116,000	755,200	-		0	Series A Common Stock
Sagimet Biosciences Inc - ...	David Happel	Director, President & CEO	Purchase of securities on an exchange or from another person at price $ 5.27 per share.	26 Mar 2024	12,100	639,200	-	5.3	63,731	Series A Common Stock
Sagimet Biosciences Inc - ...	Happel David	Director, President & CEO	Purchase of securities on an exchange or from another person at price $ 4.10 per share.	07 Dec 2023	1,600	627,100	-	4.1	6,560	Series A Common Stock
Sagimet Biosciences Inc - ...	David Happel	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	18 Jul 2023	1,011,826	1,011,826	-		-	Stock Option (Right to Buy)
Sagimet Biosciences Inc - ...	David Happel	Director, President & CEO	Sale or transfer of securities back to the company at price $ 0.00 per share.	18 Jul 2023	1,011,826	0	-		-	Stock Option (Right to Buy)

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades